Page 177 - Haematologica Vol. 107 - September 2022

ARTICLE - Rituximab with LMB-chemotherapy regimen in PMLBL M.E. Dourthe et al.
Haematologica | 107 September 2022
2176
ADM: adriamycin, doxorubicin; AraC: aracytine; VCR: vincristine; MTX: methotrexate; Cy: cyclophosphamide; pred: prednisolone; IT: intrathecal; RA: remission assessment. *A COP prephase is not mandatory but may be required one week prior to commencement of course 1 for patients requiring urgent treatment whilst awaiting histological confirmation. In case of COP prephase more intrathecal are administered. #remission assessment was required after 4 or 6 courses of chemotherapy. At the end of therapy, if PET-CT is positive, or a large residual tumor remains, then biopsy/removal of the residual mass is recommended. No treatment decisions were to be based on PET-CT results only.